CA2427765A1 - Evaluation and preservation solution - Google Patents
Evaluation and preservation solution Download PDFInfo
- Publication number
- CA2427765A1 CA2427765A1 CA002427765A CA2427765A CA2427765A1 CA 2427765 A1 CA2427765 A1 CA 2427765A1 CA 002427765 A CA002427765 A CA 002427765A CA 2427765 A CA2427765 A CA 2427765A CA 2427765 A1 CA2427765 A1 CA 2427765A1
- Authority
- CA
- Canada
- Prior art keywords
- evaluation
- solution according
- preservation solution
- serum albumin
- organ
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
Abstract
An evaluation and preservation solution for human and animal organs, tissues and parts thereof is described, wherein it comprises serum albumin at a concentration of 55-105 g/L, a scavenger and coating compound, preferably dextran compounds and derivatives thereof having essentially the same structure at a concentration of 1-55 g/L weight, and a physiological serum concentration of salts and nutrients in a physiologically acceptable medium.
Claims (15)
1. An evaluation and preservation solution for human and animal organs, tissues and parts thereof, char-acterised in that it comprises serum albumin at a concentration of 55-105 g/L, a scavenger and coating compound, preferably dextran compounds and derivatives thereof having essentially the same structure at a con-centration of 1-55 g/L and a physiological serum concen-tration of salts and nutrients in a physiologically acceptable medium.
2. An evalutaion and preservation solution according to claim 1, wherein the scavenger and coating compound has a molecular weight of from 1 and up to 250 kDa, more preferably from 20 up to 150 kDa, and is most preferably Dextran 40.
3. An evaluation and preservation solution according to any one of the preceding claims, wherein the concen-tration of serum albumin is 65-85 g/L, preferably 75 g/L
and the concentration of the scavenger and coating com-pound is 2-20 g/L, preferably 5 g/L.
and the concentration of the scavenger and coating com-pound is 2-20 g/L, preferably 5 g/L.
4. An evaluation and preservation solution according to claim 1, wherein the salts comprise one or more of so-dium, potassium, calcium, magnesium, phosphate, hydrogen carbonate and chloride ions; and the nutrients comprise one or more of physiologically acceptable carbohydrates, preferably glucose, fatty acids and amino acids.
5. An evaluation and preservation solution according to claim 1, wherein it optionally also contains one or more of the following: a vasodilator, preferably papaver-in; antibiotics; fibrinolytic components, preferably altepas; thrombocyte receptor blockers, preferably abciximab, and hormones, preferably tyroxin/triiodo-tyronin, insulin, cortison, growth hormone or anabolic steroids.
6. An evaluation and preservation solution according to claim 1, wherein it optionally also contains a pure scavenger compound, preferably allopurinol, vitamin E, vitamin C, didox or trimidox; and/or a compound having endothel coating effects.
7. An evaluation and preservation solution according to claim 1, wherein the serum albumin is human or animal serum albumin or recombinant serum albumin produced by genetic engineering.
8. An evaluation and preservation solution according to claim 7, wherein the serum albumin is partially replaced with a hyaluronic acid-based compound having a molecular weight of about 69 kDa.
9. An evaluation and preservation solution according to claim 1, wherein the organs are chosen from lungs, hearts, kidneys, livers, pancreas, small bowels, prefer-ably lungs.
10. A mixed solution ready for use based on a solu-tion according to any one of claims 1-9, wherein it also comprises red blood cells and has an EVF of 15% ~ 3% and wherein the concentration of serum albumin is 50-100 g/L, preferably 60-80 g/L, most preferably 70 g/L of the solution ready for use, and the concentration of the scavenger and coating compounds in the case of dextran compounds is 1-50 g/L, preferably 2-20 g/L, and most preferably 0,5 g/L of the solution ready for use.
11. A method for the evaluation of human and animal organs, tissues and parts thereof for transplantation, comprising the steps of perfusing the organ, tissue or part thereof with the solution according to claim 10, measuring the evaluation parameters, and optionally pre-serving the perfused and accepted organ, tissue or part thereof in said solution until transplantation thereof.
12. Method according to claim 11, wherein a lung is perfused, evaluated and optionally preserved.
13. A method for the transplantation of an organ, tissue or a part thereof from a non-heart-beating human or animal donor, in which the organ, tissue or part thereof is harvested from the donor body, is perfused with the solution according to claim 10, and evaluated, and, if the organ, tissue or part thereof is acceptable for transplantation, it is optionally preserved in said solution until it is transplanted into a donor.
14. Method according to claim 13, wherein the organ, tissue or part thereof is auto-, allo- or xenotransplant-ed.
15. Use of a solution according to claim 1 or 10 for evaluation and preservation of human and animal organs, tissues and parts thereof before transplantation.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0004032A SE0004032D0 (en) | 2000-11-03 | 2000-11-03 | Evaluation and preservation solution |
| SE0004032-9 | 2000-11-03 | ||
| US27972501P | 2001-03-30 | 2001-03-30 | |
| US60/279,725 | 2001-03-30 | ||
| PCT/SE2001/002419 WO2002035929A1 (en) | 2000-11-03 | 2001-11-05 | Evaluation and preservation solution |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2427765A1 true CA2427765A1 (en) | 2002-05-10 |
| CA2427765C CA2427765C (en) | 2012-01-24 |
Family
ID=26655291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2427765A Expired - Lifetime CA2427765C (en) | 2000-11-03 | 2001-11-05 | Evaluation and preservation solution |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US7255983B2 (en) |
| EP (1) | EP1339279B2 (en) |
| CN (1) | CN100381048C (en) |
| AT (1) | ATE330468T1 (en) |
| AU (2) | AU2002214443B2 (en) |
| CA (1) | CA2427765C (en) |
| DE (1) | DE60121027T3 (en) |
| ES (1) | ES2263674T5 (en) |
| HK (1) | HK1058610A1 (en) |
| WO (1) | WO2002035929A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11425900B2 (en) | 2011-06-22 | 2022-08-30 | Shaf Keshavjee | Modified donor organs |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8409846B2 (en) | 1997-09-23 | 2013-04-02 | The United States Of America As Represented By The Department Of Veteran Affairs | Compositions, methods and devices for maintaining an organ |
| AU2002214443B2 (en) * | 2000-11-03 | 2005-12-15 | Vitrolife Ab | Evaluation and preservation solution |
| DE10326764A1 (en) * | 2003-06-13 | 2004-12-30 | Biotest Ag | Endothelium-protective perfusion solution, an apparatus and method for preserving the endothelium in isolated hollow organs and biological vessels |
| US8465970B2 (en) | 2004-10-07 | 2013-06-18 | Transmedics, Inc. | Systems and methods for ex-vivo organ care |
| US8304181B2 (en) | 2004-10-07 | 2012-11-06 | Transmedics, Inc. | Method for ex-vivo organ care and for using lactate as an indication of donor organ status |
| US9301519B2 (en) * | 2004-10-07 | 2016-04-05 | Transmedics, Inc. | Systems and methods for ex-vivo organ care |
| US8637230B2 (en) | 2004-11-12 | 2014-01-28 | Organoflush B.V. | Composition for cold preservation and perfusion of organs |
| US9078428B2 (en) | 2005-06-28 | 2015-07-14 | Transmedics, Inc. | Systems, methods, compositions and solutions for perfusing an organ |
| WO2007009981A1 (en) * | 2005-07-15 | 2007-01-25 | Medizinische Hochschule Hannover | Medium and process for tissue cultivation |
| IL301141A (en) * | 2006-04-19 | 2023-05-01 | Transmedics Inc | Systems and methods for ex vivo organ care |
| US9457179B2 (en) | 2007-03-20 | 2016-10-04 | Transmedics, Inc. | Systems for monitoring and applying electrical currents in an organ perfusion system |
| SE531453C2 (en) * | 2007-07-06 | 2009-04-07 | Xenodevice Ab | Organ evaluation and preservation system |
| US8835104B2 (en) | 2007-12-20 | 2014-09-16 | Fenwal, Inc. | Medium and methods for the storage of platelets |
| US10750738B2 (en) | 2008-01-31 | 2020-08-25 | Transmedics, Inc. | Systems and methods for ex vivo lung care |
| US8968992B2 (en) * | 2008-03-21 | 2015-03-03 | Fenwal, Inc. | Red blood cell storage medium for extended storage |
| US8871434B2 (en) * | 2008-03-21 | 2014-10-28 | Fenwal, Inc. | Red blood cell storage medium for extended storage |
| CA2723706C (en) * | 2008-05-06 | 2020-10-20 | Vivoline Medical Ab | Apparatus for housing an organ during evaluation and preservation |
| SE534527C2 (en) * | 2009-09-24 | 2011-09-20 | Vivoline Medical Ab | Procedure, device and fluid for treating a heart after withdrawal |
| EP2482646A4 (en) | 2009-09-25 | 2017-07-26 | Vivoline Medical AB | Container and supporting structure for housing an organ |
| US11864553B2 (en) | 2009-10-23 | 2024-01-09 | Fenwal, Inc. | Methods and systems for providing red blood cell products with reduced plasma |
| SE534862C2 (en) | 2010-05-14 | 2012-01-24 | Vivoline Medical Ab | Use of a medical fluid for treatment of a withdrawn organ |
| AU2012240016B2 (en) | 2011-04-07 | 2016-11-10 | Fenwal, Inc. | Automated methods and systems for providing platelet concentrates with reduced residual plasma volumes and storage media for such platelet concentrates |
| AU2012242578B2 (en) * | 2011-04-14 | 2016-07-21 | Transmedics, Inc. | Organ care solution for ex-vivo machine perfusion of donor lungs |
| EP2763526A4 (en) * | 2011-10-03 | 2015-06-03 | Vivoline Medical Ab | Medical fluid comprising globulin and its use for preservation of harvested organs |
| WO2014059316A1 (en) * | 2012-10-12 | 2014-04-17 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Compositions and methods for organ preservation |
| US9888680B2 (en) * | 2013-04-04 | 2018-02-13 | The Trustees Of Columbia University In The City Of New York | Functional recovery of human lungs for transplantation |
| EP2821081A1 (en) | 2013-07-05 | 2015-01-07 | ResuSciTec GmbH | Protective solution for preventing or reducing reperfusion injury of the brain and the whole body |
| CA2947711A1 (en) * | 2014-05-01 | 2015-11-05 | Catherine E. Berry | A modified single dose, microplegic approach to cardioplegia for the adult heart |
| AU2015271799B2 (en) | 2014-06-02 | 2019-07-11 | Transmedics, Inc. | Ex vivo organ care system |
| EP3229588A4 (en) | 2014-12-12 | 2019-03-13 | Freed, Darren | Apparatus and method for organ perfusion |
| CN104542578B (en) * | 2015-02-05 | 2017-01-18 | 广州赛莱拉干细胞科技股份有限公司 | Cell preservation solution and preparation method and applications thereof |
| US10874098B2 (en) | 2015-04-03 | 2020-12-29 | Tx Innovations B.V. | Organ preservation composition |
| GB201505987D0 (en) * | 2015-04-08 | 2015-05-20 | Univ Dublin | A lung perfusion solution and use thereof for the ex-vivo preservation of a mammalian lung |
| FR3035407B1 (en) | 2015-04-23 | 2022-06-17 | Francais Du Sang Ets | METHOD FOR PRESERVING CELLS, TISSUES OR ORGANS IN HYPOTHERMIA |
| CN104804556A (en) * | 2015-04-28 | 2015-07-29 | 北京建筑大学 | Novel environment-friendly anti-corrosion coating used on surface of metal and application of novel environment-friendly anti-corrosion coating |
| GB201511207D0 (en) | 2015-06-25 | 2015-08-12 | Xvivo Perfusion Ab | Isolated organ evaluation and treatment |
| CA2997267A1 (en) | 2015-09-09 | 2017-03-16 | Transmedics, Inc. | Aortic cannula for ex vivo organ care system |
| FR3040860B1 (en) * | 2015-09-10 | 2020-05-15 | Universite de Bordeaux | INJECTABLE STORAGE MEDIUM FOR STORAGE OF PLACENTAL BLOOD, BONE MARROW AND PERIPHERAL BLOOD CELLS |
| WO2017134192A1 (en) | 2016-02-04 | 2017-08-10 | Xvivo Perfusion Ab | Ex vivo lung simulator |
| CN105954526B (en) * | 2016-04-26 | 2017-10-10 | 南华大学 | A kind of enzyme immunoassay (EIA) method of insulin |
| US10091986B2 (en) | 2016-05-09 | 2018-10-09 | Xor-Labs Toronto Inc. | Organ perfusion device and method |
| DK3448149T3 (en) * | 2017-01-17 | 2019-11-04 | Xvivo Perfusion Ab | ORGAN CONSERVATION AND / OR PERFUSION SOLUTIONS |
| CN107980767B (en) * | 2018-01-10 | 2018-10-30 | 暨赛再生医学科技有限公司 | A kind of preservation liquid of the EPC of long-term preservation overexpression ANG-1 |
| CA3107918A1 (en) | 2018-08-03 | 2020-02-06 | VeriGraft AB | Methods of preparing personalized blood vessels |
| EP3952643A4 (en) * | 2019-04-12 | 2023-01-11 | UGLX Research AB | Method and apparatus for reconditioning organs |
| WO2020209787A1 (en) * | 2019-04-12 | 2020-10-15 | Uglk Science Ab | Method and apparatus for reconditioning kidneys |
| CN111700063B (en) * | 2020-06-29 | 2021-03-30 | 广州瑞铂茵健康科技有限公司 | Preservation method of umbilical cord specimen |
| GB202011427D0 (en) | 2020-07-23 | 2020-09-09 | Xvivo Perfusion Ab | Organ preservation and/or perfusion solution |
| US20240049700A1 (en) * | 2021-01-04 | 2024-02-15 | Biosip Ab | Lipid layer preservation |
| WO2022233642A1 (en) | 2021-05-06 | 2022-11-10 | Xvivo Perfusion Ab | Methods for removing leucocytes from isolated organs |
| WO2024018452A1 (en) | 2022-07-18 | 2024-01-25 | Yeda Research And Development Co. Ltd. | Albumin protein variants, production thereof and uses of same |
| WO2024018051A1 (en) | 2022-07-22 | 2024-01-25 | Grifols Worldwide Operations Limited | Stable plasmin compositions for organ preservation and reconditioning |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE940059C (en) * | 1953-03-12 | 1956-03-08 | Behringwerke Ag | Process for the manufacture of infusion preparations for circulatory filling |
| SU1109110A1 (en) | 1981-06-30 | 1984-08-23 | Институт Физиологии Им.А.И.Караева | Composition for preserving liver |
| NO166836C (en) * | 1985-03-14 | 1991-09-11 | Univ California | PROCEDURE FOR TREATMENT OF AN ORGAN TRANSPLANT. |
| JPS62151155A (en) | 1985-09-17 | 1987-07-06 | Ajinomoto Co Inc | Production of seasoning using cheese whey as raw material |
| US4798824A (en) | 1985-10-03 | 1989-01-17 | Wisconsin Alumni Research Foundation | Perfusate for the preservation of organs |
| US4898824A (en) * | 1986-12-09 | 1990-02-06 | Miles Inc. | Crosslinked polyacrylamide-sulfhydryl polymer for immobilization of biologically active substances |
| US5051352A (en) * | 1987-10-07 | 1991-09-24 | The Regents Of The University Of California | Apparatus and method of preserving the viability of animal organs |
| US4920044A (en) * | 1988-11-08 | 1990-04-24 | The Cleveland Clinic Foundation | Intracellular flush solution for preserving organs |
| GB9024223D0 (en) | 1990-11-07 | 1990-12-19 | Fermentech Ltd | Production of hyaluronic acid |
| US5217860A (en) * | 1991-07-08 | 1993-06-08 | The American National Red Cross | Method for preserving organs for transplantation by vitrification |
| CA2061567C (en) * | 1992-02-20 | 1998-02-03 | Rudolf E. Falk | Use of hyaluronic acid to repair ischemia reperfusion damage |
| WO1994021116A1 (en) * | 1993-03-16 | 1994-09-29 | Alliance Pharmaceutical Corp. | Preservation solution and method for warm organ preservation |
| US5360389A (en) * | 1993-05-25 | 1994-11-01 | Chenette Philip E | Methods for endometrial implantation of embryos |
| JP3715312B2 (en) * | 1993-06-04 | 2005-11-09 | バイオタイム インク | Plasma-like solution |
| US6375613B1 (en) * | 1994-05-20 | 2002-04-23 | Breonics, Inc. | Prognostic testing of organs intended for transplantation |
| US5643712A (en) * | 1994-05-20 | 1997-07-01 | Brasile; Lauren | Method for treating and rendering grafts nonthrombogenic and substantially nonimmunogenic using an extracellular matrix coating |
| WO1995031897A1 (en) * | 1994-05-20 | 1995-11-30 | Vec Tec, Inc. | Method and apparatus monitoring viability of transplantable organs |
| US5580714A (en) | 1995-03-08 | 1996-12-03 | Celox Laboratories, Inc. | Cryopreservation solution |
| SE505499C2 (en) | 1995-12-15 | 1997-09-08 | Stiftelsen Facthor | Storage solution for organs and tissues or parts thereof of humans and animals containing calcium and nitroglycerin, their use and method of storage therewith |
| IT1287227B1 (en) * | 1996-04-04 | 1998-08-04 | Fidia Spa In Amministrazione S | HYALURONIC ACID AS A COMPONENT OF THE CORNEA PRESERVATION LIQUID |
| US5843024A (en) * | 1996-05-17 | 1998-12-01 | Breonics, Inc. | Solution and process for resuscitation and preparation of ischemically damaged tissue |
| DE19652922C2 (en) | 1996-12-19 | 1999-07-29 | O & K Mining Gmbh | Hydraulic circuit for a hydraulic excavator |
| US5948609A (en) * | 1997-12-03 | 1999-09-07 | Carter; Daniel C. | Oxygen-transporting albumin-based blood replacement composition and blood volume expander |
| JPH11246301A (en) * | 1998-02-27 | 1999-09-14 | Denki Kagaku Kogyo Kk | Organ preserving solution |
| GB9902412D0 (en) | 1999-02-03 | 1999-03-24 | Fermentech Med Ltd | Process |
| GB9902652D0 (en) | 1999-02-05 | 1999-03-31 | Fermentech Med Ltd | Process |
| AU2002214443B2 (en) * | 2000-11-03 | 2005-12-15 | Vitrolife Ab | Evaluation and preservation solution |
-
2001
- 2001-11-05 AU AU2002214443A patent/AU2002214443B2/en not_active Expired
- 2001-11-05 CN CNB018198228A patent/CN100381048C/en not_active Expired - Lifetime
- 2001-11-05 ES ES01982986T patent/ES2263674T5/en not_active Expired - Lifetime
- 2001-11-05 EP EP01982986A patent/EP1339279B2/en not_active Expired - Lifetime
- 2001-11-05 DE DE60121027T patent/DE60121027T3/en not_active Expired - Lifetime
- 2001-11-05 CA CA2427765A patent/CA2427765C/en not_active Expired - Lifetime
- 2001-11-05 AT AT01982986T patent/ATE330468T1/en active
- 2001-11-05 US US10/415,740 patent/US7255983B2/en not_active Expired - Lifetime
- 2001-11-05 WO PCT/SE2001/002419 patent/WO2002035929A1/en active IP Right Grant
- 2001-11-05 AU AU1444302A patent/AU1444302A/en active Pending
-
2004
- 2004-03-02 HK HK04101533A patent/HK1058610A1/en not_active IP Right Cessation
-
2007
- 2007-08-13 US US11/889,460 patent/US8012677B2/en not_active Expired - Fee Related
-
2011
- 2011-07-08 US US13/178,655 patent/US8980541B2/en not_active Expired - Fee Related
-
2015
- 2015-02-09 US US14/617,340 patent/US20150150240A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11425900B2 (en) | 2011-06-22 | 2022-08-30 | Shaf Keshavjee | Modified donor organs |
Also Published As
| Publication number | Publication date |
|---|---|
| US7255983B2 (en) | 2007-08-14 |
| EP1339279A1 (en) | 2003-09-03 |
| US20080057488A1 (en) | 2008-03-06 |
| DE60121027T3 (en) | 2011-06-09 |
| DE60121027T2 (en) | 2007-01-04 |
| EP1339279B1 (en) | 2006-06-21 |
| ATE330468T1 (en) | 2006-07-15 |
| WO2002035929A1 (en) | 2002-05-10 |
| AU2002214443B2 (en) | 2005-12-15 |
| ES2263674T3 (en) | 2006-12-16 |
| US20110269112A1 (en) | 2011-11-03 |
| CA2427765C (en) | 2012-01-24 |
| US20040029096A1 (en) | 2004-02-12 |
| CN1477926A (en) | 2004-02-25 |
| CN100381048C (en) | 2008-04-16 |
| AU1444302A (en) | 2002-05-15 |
| US20150150240A1 (en) | 2015-06-04 |
| DE60121027D1 (en) | 2006-08-03 |
| US8980541B2 (en) | 2015-03-17 |
| HK1058610A1 (en) | 2004-05-28 |
| ES2263674T5 (en) | 2011-04-01 |
| US8012677B2 (en) | 2011-09-06 |
| EP1339279B2 (en) | 2010-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2427765A1 (en) | Evaluation and preservation solution | |
| AU2002214443A1 (en) | Evaluation and preservation solution | |
| US5002965A (en) | Use of ginkgolides to prevent reperfusion injury in organ transplantation | |
| CA1270199A (en) | Preservation of living tissue | |
| US6060233A (en) | Methods for the lyophilization of platelets, platelet membranes or erythrocytes | |
| WO1997035472B1 (en) | Use of arabinogalactan in cell cryopreservation media | |
| WO2000064254A1 (en) | Novel organ preservation solution | |
| Treckmann et al. | Retrograde oxygen persufflation preservation of human livers: a pilot study | |
| CA2066374A1 (en) | Solution for perfusing primates | |
| Karck et al. | Ischemic preconditioning enhances donor heart preservation1 | |
| KR100855354B1 (en) | flush preservation solution | |
| US20150111193A1 (en) | Methods and solutions for tissue preservation | |
| Kuzmin et al. | Effects of preconditioning on myocardial interstitial levels of ATP and its catabolites during regional ischemia and reperfusion in the rat | |
| Hausen et al. | In vivo measurement of lung preservation solution efficacy: comparison of LPD, UW, EC and low K+-EC following short and extended ischemia | |
| Salgado | Non beating heart donors as a possible source for liver transplantation | |
| CA2266012A1 (en) | Flush-storage solution for donor organs | |
| CA2850714C (en) | Medical fluid comprising globulin and its use for preservation of harvested organs | |
| CA2139547A1 (en) | Lung graft preservative composition and a method for viable preservation of lung grafts | |
| US7288551B1 (en) | Solution for the preservation of hearts | |
| CA2383324C (en) | Solution for the preservation of hearts | |
| KR100304594B1 (en) | Composition for the Preservation of Organs and Blood Cells | |
| Amir et al. | Improved viability and reduced apoptosis in subzero 21 hours preservation of transplanted rat hearts using antifreeze proteins | |
| Pegg et al. | Permeation of rabbit kidneys with cryoprotective agents | |
| Madden et al. | Preliminary studies of the cryopreservation of bovine corneal endothelium |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |